# Aiolos Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aiolos-bio

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aiolosbio.com
- Total disclosed funding: $245M
- Latest round: Series A (Oct 24, 2023)
- Investors on record: 5

## About

Based in Massachusetts, US, and founded in 2023 by co-founders Khurem Farooq and Tony Adamis, Aiolos Bio, Inc. offers a wide range of products catering to various immune conditions, such as asthma, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). In October 2023, Aiolos Bio, Inc. raised USD 245 million in Series A funding co-led by investors Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with participation from another investor, RA Capital Management. In January 2024, GlaxoSmithKline Plc agreed to acquire Aiolos Bio, Inc. for USD 1 billion.

The company offers an anti-TSLP (thymic stromal lymphopoietin) asset, AIO-001, a monoclonal antibody specifically designed to target and block TSLP, a known driver of inflammation in conditions like asthma. This approach represents a paradigm shift in the management of asthma, providing patients with a significantly reduced treatment burden, thereby allowing them to lead fuller lives.

The company plans to use the October 2023 funding to support the advancement of its Phase 2-Ready TSLP antibody.

## Funding rounds

- Series A, Oct 24, 2023, $245M — Atlas Venture, Sofinnova Investments, Forbion, RA Capital Management, Bain Capital Life Sciences

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Bain Capital Life Sciences — Series A